---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006089"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:14:59.234390+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences reports Q3 net loss $27.9M; RETHINK-ALZ top-line data expected by end-2024

## Summary
- Net loss $27.9M ($0.58 per share) vs $25.7M ($0.61) in Q3 2023; cash $149M at Sep 30, 2024.
- Top-line results from Phase 3 RETHINK-ALZ trial (simufilam) expected before end of 2024.
- DSMB recommended both Phase 3 studies continue as planned at Sep 2024 meeting.
- Year-end 2024 cash estimated $117-127M; $40M SEC settlement in escrow excluded.
- Open-label extension study enrolled over 1,040 patients; 88% opt-in rate.

## SEC filing metadata
- accession: 0001171843-24-006089
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184324006089/0001171843-24-006089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184324006089/f8k_110724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006089
- JSON: https://secwatch.observer/filing/0001171843-24-006089.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006089.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.